Stock news: 1. CSPC (01093.HK): Lenkanizumab injection has been approved for clinical trials in China. 2...
2025-09-26 01:07:18
< b > Stock News: < br > < span class = "section-news" > 1. CSPC (01093.HK): Lencarnimab Injection has been approved for clinical trials in China. < br > < span class = "section-news" > 2. XPeng Motors (09868.HK) issued 3.2472 million shares of Class A common stock under the share plan. < br > < span class = "section-news" > 3. Fuyao Glass (03606.HK) will pay an interim dividend of HK $0.986712 per share on November 13. < br > < span class = "section-news" > 4. Alibaba (09988.HK): Granted 10% of the company's new ordinary shares to the board of directors. < br > < span class = "section-news" > 5. 02517.HK intends to use up to 100 million Hong Kong dollars to further repurchase H shares. < br > < span class = "section-news" > 6. Jihong (02603.HK) expects net profit attributable to the parent to increase by 55% -65% year-on-year in the first three quarters. < br > < span class = "section-news" > 7. New World Development (00017.HK) received 5.90 billion Hong Kong dollar loan financing, secured by Victoria Harbour Cultural Exchange Property. < br > < span class = "section-news" > 8. Tianjin Port Development (03382.HK) Subsidiary plans to acquire 5% of Eurasia International Corporation for 95.403 million yuan. < br > < span class = "section-news" > 9. Times China Holdings (01233.HK): Final deadline for restructuring support agreement extended to December 31. < br > < span class = "section-news" > 10. Tianjin Port Development (03382.HK) plans to acquire 40% of Alliance International Corporation for 723 million yuan, increasing its shareholding to 100%. < br > < span class = "section-news" > 11. New World general merchandise China (00825.HK) announced its annual results: net profit of HK $2528.5 million, an increase of 89.91% year-on-year. < br > < span class = "section-news" > 12. Shanghai Pharmaceutical (02607.HK): Shanghai Shangshi Yangtze River Delta transferred 40% equity of Shanghai Shangshi Pharmaceutical Group to Shanghai Shangshi for about 6.7215 billion yuan. < br > < span class = "section-news" > 13. Huiyuan Tongchuang Technology (01116.HK) will establish a joint venture with EPS to be responsible for the production of phase change energy storage products and the industrialization of the Chinese market.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
